Semaglutide, tirzepatide, and retatrutide, what each one does, how they differ, and why the progression matters. Not medical advice. Just what I've learned.
Semaglutide, tirzepatide, and retatrutide are three generations of the same idea, hormone receptor pathways that regulate appetite and metabolism. Each one adds a receptor, and the efficacy climbs with it. Semaglutide and tirzepatide are FDA-approved today. Retatrutide is still in Phase 3, the next step in the same progression.
These three drugs share a family resemblance, they all work through hormone receptor pathways that govern appetite, insulin response, and metabolic regulation. But they're not interchangeable. Each one activates a different combination of receptors, which is why the efficacy numbers climb so dramatically from one to the next. Understanding what those receptors actually do makes the whole story click into place. Think of it as a signal upgrade, same conversation, more channels open.
Each adds a receptor, and each addition meaningfully changes what the drug accomplishes in your body.
A synthetic analog of the GLP-1 hormone, the one your gut releases after eating. Semaglutide slows gastric emptying, reduces appetite signals in the brain, and improves insulin secretion. Subcutaneous weekly injection or daily oral tablet (Rybelsus). The drug that changed the conversation about obesity.
Adds GIP receptor activation to the GLP-1 mechanism. GIP (glucose-dependent insulinotropic polypeptide) works in both the pancreas and fat tissue, enhancing how your body responds to insulin while also reducing fat storage directly. The combination produces significantly greater weight loss than semaglutide alone, and better tolerability in many patients.
Adds glucagon receptor agonism to the dual mechanism above. Glucagon, typically thought of as raising blood sugar, also drives significant fat burning and energy expenditure when activated in combination with the other two. The triple action creates a metabolic effect no prior drug has matched, including the highest documented weight loss in any GLP-1 class trial to date.
Each receptor unlocks a different biological channel. Adding channels doesn't just add effects, it multiplies them.
Released by intestinal L-cells after eating. Signals the brain to reduce hunger, tells the pancreas to release insulin, and slows how quickly food leaves the stomach. All three drugs activate this receptor. It's the foundation the class is built on, proven to reduce cardiovascular events even before significant weight loss occurs.
Also released after eating, from K-cells in the small intestine. Acts on the pancreas, fat tissue, and bone. In the presence of GLP-1 agonism, GIP receptor activation dramatically amplifies insulin sensitivity and reduces fat storage. It may also reduce the nausea some patients experience on GLP-1 alone, improving tolerability at higher doses.
Glucagon's reputation is "raises blood sugar", which is accurate when it acts alone. But in the context of combined GLP-1 and GIP agonism, activating the glucagon receptor has a different net effect: it drives fat oxidation, increases energy expenditure, and appears to have meaningful effects on liver fat and cardiovascular lipid profiles. Retatrutide is the only drug in this class that activates all three.
Semaglutide primarily works through appetite and insulin. Adding GIP (tirzepatide) brings fat tissue signaling directly into the picture. Adding glucagon (retatrutide) then activates a third metabolic lever, energy expenditure itself. It's not additive in a simple arithmetic sense. These pathways interact and amplify each other in ways that explain why the weight loss data climbs so steeply from one generation to the next.
Across randomized controlled trials at highest approved (or studied) doses. Individual results vary significantly based on dose, duration, lifestyle, and starting weight.
Weight loss is the headline. But the systemic effects are where this class gets genuinely remarkable, particularly for people carrying significant metabolic burden.
Semaglutide's SELECT trial showed a 20% reduction in major cardiovascular events in non-diabetic adults with obesity. Tirzepatide shows LDL and blood pressure improvements. Retatrutide adds meaningful triglyceride and PCSK9 reduction through glucagon receptor effects.
All three improve insulin sensitivity. In retatrutide Phase 2 trials, 72% of participants with prediabetes at baseline returned to normal blood glucose by week 48. The addition of GIP and glucagon agonism drives substantially better glycemic control than GLP-1 alone.
Fatty liver disease (NAFLD/NASH) is closely linked to metabolic syndrome. All three drugs reduce hepatic fat, with retatrutide showing the largest reductions in Phase 2. Liver health improvements often begin before significant weight loss is achieved.
TRIUMPH-4 Phase 3 data for retatrutide: 75.8% reduction in knee osteoarthritis pain scores at 68 weeks. More than 1 in 8 participants reported complete freedom from knee pain. Weight reduction alone doesn't explain the magnitude, direct anti-inflammatory effects are thought to play a role.
GLP-1 receptors are present in the brain, not just the gut. All three drugs show effects on dopamine pathways, reward signaling, and addictive behavior reduction. Patients consistently report improved energy and cognitive clarity, beyond what weight loss alone explains in exit interviews.
Semaglutide has trial data (FLOW trial) showing meaningful reduction in kidney disease progression. Tirzepatide and retatrutide are expected to show similar or stronger nephroprotective signals, particularly relevant for those with metabolic syndrome and elevated glucose history.
Significant, sustained weight loss does remarkable things systemically, but it also creates real skin challenges. Rapid fat loss can cause skin laxity, barrier disruption, and texture changes that no medication addresses directly. Pairing your GLP-1 protocol with targeted peptide support (GHK-Cu, KPV, collagen) is where the full picture comes together. The drug handles the metabolic work. The supporting protocols handle what the scale doesn't show.
Phase 3 results are significant enough to understand even now, with the clear caveat that this drug is not approved and cannot be legally compounded.
Triple agonism does what dual agonism couldn't, and the data reflects it clearly.
Retatrutide is currently in Phase 3 clinical trials. It is not FDA approved. Under existing federal law, it cannot be used in compounding preparations. This section exists for context and education only, not as a treatment option to pursue outside of an approved clinical trial.
The glucagon receptor is the key differentiator. While GLP-1 and GIP primarily act on appetite and insulin, glucagon receptor agonism drives energy expenditure and fat oxidation directly, which explains why the weight loss numbers jump so sharply. The liver fat reductions follow from the same mechanism.
As of early 2026, Eli Lilly has submitted retatrutide data for FDA review. Approval, if it comes, would represent the first triple agonist to reach the market. No compounded version will be legal even post-approval unless a separate shortage designation specifically allows it, which the FDA has explicitly noted it will not.
Phase 3 is the final stage of human clinical trials before FDA submission, large-scale, randomized, controlled. Eli Lilly ran multiple TRIUMPH sub-trials covering weight loss, cardiovascular outcomes, kidney disease, and osteoarthritis. The breadth of the program signals how seriously they view the systemic potential.
Retatrutide is investigational and not FDA approved as of this writing. The FDA has explicitly stated it cannot be used in compounding under federal law, regardless of shortage status or provider request. This information is presented as educational context only. Currently approved options in this class are semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Any treatment decisions belong between you and your provider.
Not prescriptive. Just context that's helped me, and that I wish someone had laid out clearly at the start.
These drugs affect insulin, thyroid, kidney function, liver enzymes, and lipids. Baseline labs before starting, and regular monitoring during, minimum every 3–6 months, matter. Optimal targets for GLP-1 users differ from standard lab normals in meaningful ways. Know the difference before you interpret your results.
Rapid weight loss on any of these drugs risks lean muscle mass loss alongside fat. High protein intake (1g+ per pound of lean body mass) and resistance training are the two best tools against this. GLP-1s suppress appetite broadly, you have to be intentional about protein, because you won't feel as hungry for it.
Semaglutide and tirzepatide have been available through compounding pharmacies during drug shortage periods. FDA shortage status changes, compounded availability is not guaranteed and varies by drug, pharmacy, and state. Always verify current legal status and use only licensed 503A/503B compounders. Retatrutide cannot be compounded, period.
GLP-1 face. Loose skin. Texture changes. These aren't vanity concerns, they're common, documented experiences for anyone losing significant weight. The earlier you start proactive skin support, the better the outcome. Collagen production, barrier health, and skin architecture all respond to the same weight loss speed that changes your metabolic picture.
Plain-language definitions for everything referenced in this guide.
Evidence strength varies by drug and outcome. Semaglutide and tirzepatide have extensive trial data; retatrutide data is Phase 2–3 and ongoing.
This guide is for informational and educational purposes only. It is not medical advice and does not constitute a recommendation for any specific treatment. I'm sharing what I've learned on my own journey, not prescribing anything for yours. Any medication decision, including GLP-1 therapy, should be made with a qualified healthcare provider who knows your full history. Retatrutide is investigational, not FDA approved, and legally cannot be compounded. Always verify current FDA status and consult a licensed provider before starting or changing any protocol.